We are live on ! Find out more
SFM

Sphera Funds Management Portfolio holdings

AUM $630M
1-Year Est. Return 108.65%
This Fund
S&P 500
This Quarter Est. Return
-2.89%
1 Year Est. Return
+108.65%
3 Year Est. Return
+217.64%
5 Year Est. Return
+342.91%
10 Year Est. Return
+2,254.45%
AUM
$935M
AUM Growth
+$227M
Cap. Flow
+$310M
Cap. Flow %
33.15%
Top 10 Hldgs %
70.78%
Holding
86
New
20
Increased
18
Reduced
12
Closed
29

Top Buys

Rank Stock Value
1
XBI icon
State Street SPDR S&P Biotech ETF
XBI
+$32.9M
2
LLY icon
Eli Lilly
LLY
+$18.6M
3
FIVN icon
FIVE9
FIVN
+$11.3M
4
NICE icon
Nice
NICE
+$11.2M
5
META icon
Meta Platforms (Facebook)
META
+$9.65M

Top Sells

Rank Stock Value
1
PFE icon
Pfizer
PFE
+$26.7M
2
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$16.3M
3
KYMR icon
Kymera Therapeutics
KYMR
+$15.6M
4
ZIM icon
ZIM Integrated Shipping Services
ZIM
+$10.8M
5
GNRC icon
Generac Holdings
GNRC
+$9.81M

Sector Composition

Rank Sector Weight
1 Healthcare 47.28%
2 Technology 3.05%
3 Communication Services 0.86%
4 Financials 0.27%
5 Consumer Discretionary 0.26%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
QQQ icon
1
CALL
Invesco QQQ Trust
QQQ
$453B
$278M 29.77%
+992,800
New +$308M
SPY icon
2
CALL
State Street SPDR S&P 500 ETF Trust
SPY
$790B
$75.3M 8.05%
+199,500
New +$81.7M
AZN icon
3
AstraZeneca
AZN
$263B
$52.8M 5.64%
399,305
-19,104
-5% -$2.51M
JNJ icon
4
Johnson & Johnson
JNJ
$618B
$49.1M 5.25%
276,451
-18,572
-6% -$3.31M
LLY icon
5
Eli Lilly
LLY
$1.02T
$42.9M 4.59%
132,250
+61,955
+88% +$18.6M
SNY icon
6
Sanofi
SNY
$103B
$42.3M 4.53%
846,215
-126,200
-13% -$6.7M
ABBV icon
7
AbbVie
ABBV
$443B
$33.4M 3.58%
218,385
+27,391
+14% +$4.19M
XBI icon
8
State Street SPDR S&P Biotech ETF
XBI
$9.95B
$32.5M 3.48%
+437,748
New +$32.9M
NVO
9
Novo Nordisk
NVO
$208B
$29.1M 3.12%
522,880
+48,080
+10% +$2.67M
MRK icon
10
Merck
MRK
$322B
$26M 2.78%
285,000
+6,800
+2% +$603K
TEVA icon
11
CALL
Teva Pharmaceuticals
TEVA
$40.8B
$25.4M 2.72%
3,381,600
+1,491,600
+79% +$13M
SNDX icon
12
Syndax Pharmaceuticals
SNDX
$1.69B
$21.9M 2.34%
1,139,329
-138,084
-11% -$2.3M
ALT icon
13
Altimmune
ALT
$552M
$16.3M 1.74%
1,392,884
+85,931
+7% +$530K
XBI icon
14
CALL
State Street SPDR S&P Biotech ETF
XBI
$9.95B
$14.9M 1.59%
+200,000
New +$15M
SWTX
15
DELISTED
SpringWorks Therapeutics
SWTX
$13.2M 1.41%
536,664
+76,639
+17% +$2.8M
FIVN icon
16
FIVE9
FIVN
$2.11B
$12.8M 1.37%
140,968
+111,269
+375% +$11.3M
KDNY
17
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$11.3M 1.2%
643,731
+150,054
+30% +$2.36M
CRNX icon
18
Crinetics Pharmaceuticals
CRNX
$8.84B
$10.9M 1.17%
586,820
+64,873
+12% +$1.29M
ALNY icon
19
CALL
Alnylam Pharmaceuticals
ALNY
$27.5B
$10.9M 1.17%
+75,000
New +$10.6M
NICE icon
20
Nice
NICE
$5.79B
$10.7M 1.14%
+55,482
New +$11.2M
MRUS
21
DELISTED
Merus
MRUS
$9.26M 0.99%
409,161
+20
+0% +$418
ISEE
22
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$9.26M 0.99%
962,470
+188,340
+24% +$2.36M
KURA icon
23
Kura Oncology
KURA
$800M
$9.07M 0.97%
494,595
-123,649
-20% -$1.78M
RLMD icon
24
Relmada Therapeutics
RLMD
$557M
$8.87M 0.95%
466,830
+175,578
+60% +$3.83M
TEVA icon
25
Teva Pharmaceuticals
TEVA
$40.8B
$8.63M 0.92%
1,147,878
+315,000
+38% +$2.74M
1
2 3 4

Similar funds

VIM
Vancity Investment Management Vancouver, British Columbia, Canada $629M AUM 2.49% 1-Year Est. Return
KCMH
Keywise Capital Management (HK) Hong Kong $630M AUM 81.01% 1-Year Est. Return
FCFC
First Commonwealth Financial Corp Indiana, Pennsylvania $629M AUM 20.47% 1-Year Est. Return
BI
BlueSpruce Investments Chicago, Illinois $631M AUM 11.83% 1-Year Est. Return
PWW
Pettyjohn Wood & White Lynchburg, Virginia $628M AUM 20.96% 1-Year Est. Return
TTSTC
Texas Treasury Safekeeping Trust Company Austin, Texas $628M AUM 15.58% 1-Year Est. Return
SWP
Summit Wealth Partners Orlando, Florida $632M AUM 9.71% 1-Year Est. Return
EIM
Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return

Sphera Funds Management's Q2 2022 Portfolio in Review

As of Q2 2022, Sphera Funds Management held 86 positions worth $935M, up 32% from $708M the previous quarter. Its ten largest holdings account for 71% of the portfolio.

Sphera Funds Management deployed $310M of net new capital in Q2 2022, opening 20 new positions and adding to 18 existing holdings. Its largest new stake was State Street SPDR S&P Biotech ETF: 437,748 shares worth $32.5M.

By sector, the portfolio is most concentrated in Healthcare at 47% of assets, down from 72% a quarter earlier, followed by Technology and Communication Services.

On the sell side, the largest reduction was Generac Holdings, an estimated $9.81M trimmed.

  • Sphera Funds Management's largest Q2 2022 buy was State Street SPDR S&P Biotech ETF: 437,748 shares worth $32.5M.
  • Sphera Funds Management added most to Eli Lilly in Q2 2022, an estimated $18.6M increase.
  • Sphera Funds Management's biggest Q2 2022 reduction was Generac Holdings, cutting an estimated $9.81M.
  • Sphera Funds Management fully exited Pfizer in Q2 2022, selling an estimated $26.7M.
  • Sphera Funds Management's ten largest holdings make up 71% of its $935M portfolio in Q2 2022.
  • Sphera Funds Management opened 20 new positions and closed 29 in Q2 2022.
  • Sphera Funds Management's portfolio value rose 32% quarter-over-quarter to $935M.

Based on Sphera Funds Management's 13F filing for Q2 2022, filed 15 Aug 2022.